Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
Clinical trial NCT07010302 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07010302
- Sponsor
- Massachusetts General Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2030-01-01
- Enrollment
- 540
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.